SignatureFD’s BioXcel Therapeutics BTAI Stock Holding History

SignatureFD’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3	Closed	-$1K	–	3154
2021 Q4	$1K	Hold	3	–	–	﹤0.01%	2879
2021 Q3	$1K	Buy	+3	New	+$1.32K	﹤0.01%	2783

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SignatureFD's BTAI Position: Q1 2022 in Review

SignatureFD sold out of BioXcel Therapeutics (BTAI) in Q1 2022, closing a stake of 3 shares — an estimated $1K sold.

SignatureFD first reported a position in BTAI in Q3 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

SignatureFD reported no remaining BioXcel Therapeutics position as of Q1 2022 after selling out during the quarter.
SignatureFD sold 3 BioXcel Therapeutics shares in Q1 2022, an estimated $1K.
SignatureFD first reported a position in BioXcel Therapeutics in Q3 2021 and held it in 2 quarters.
SignatureFD's BioXcel Therapeutics position peaked at $1K in Q4 2021.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on SignatureFD's 13F filing for Q1 2022, filed 2 May 2022.